clinical trials

News

Packets of Verzenio fanned out on display

Lilly raises stakes in Novartis battle with Verzenio data

Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.

News

Regeneron preps filings for myasthenia gravis drug

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

News

Diabetics on Lilly's orforglipron shed 10.5% of their weight

Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.

News

Dynavax has GSK's shingles vaccine in its sights

Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax wants to knock off its crown.

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

Viking felled by dropout rates in oral obesity drug trial

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

Lilly raises stakes in Novartis battle with Verzenio data

Regeneron preps filings for myasthenia gravis drug

Diabetics on Lilly's orforglipron shed 10.5% of their weight

Dynavax has GSK's shingles vaccine in its sights

Nicox plans filings for glaucoma after phase 3 win

Viking felled by dropout rates in oral obesity drug trial

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks